Li, Zhanzhuo
Czechowicz, Agnieszka
Scheck, Amelia
Rossi, Derrick J. http://orcid.org/0000-0003-0029-1293
Murphy, Philip M.
Article History
Received: 13 July 2018
Accepted: 20 December 2018
First Online: 6 February 2019
Competing interests
: Z.L., A.C., D.J.R., and P.M.M. are listed as inventors on a patent application disclosing CD117 antibody-drug-conjugates as a conditioning agent in allotransplantation filed with the US Patent and Trademark Office. Additional disclosures for A.C.: inventor, US patent applications (US 12/447,634; US 14/536,319; US 15/025,222; and US 15/148,837); Third Rock Ventures: Consultancy; GV: Salary; Global Blood Therapeutics: Equity Ownership, Consultancy; Editas Medicines: Equity Ownership, Patents & Royalties; Magenta Therapeutics: Equity Ownership, Patents & Royalties; Forty Seven Inc: Patents & Royalties, Beam Therapeutics: Equity Ownership, Consultancy. Additional disclosures for D.J.R.: Inventor, US patent application (US 14/509,787; US 15/148,837); Moderna Therapeutics: Equity Ownership, Patents & Royalties; Intellia Therapeutics: Equity Ownership, Patents & Royalties, Consultant; Vor Biopharma, Equity Ownership, Consultant; Magenta Therapeutics: Equity Ownership, Patents & Royalties; Stelexis Therapeutics: Equity Ownership, Consultant, Director; Convelo Therapeutics: Equity Ownership, Consultant, Director. The remaining authors declare no competing interests.